Aelis Farma Valuation
Is AELIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AELIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AELIS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AELIS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AELIS?
Key metric: As AELIS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is AELIS's PS Ratio? | |
|---|---|
| PS Ratio | 3.5x |
| Sales | €10.78m |
| Market Cap | €38.13m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | -4.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AELIS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.4x | ||
ALGEN genOway Société anonyme | 1.2x | n/a | €34.2m |
ALOPM Oncodesign Precision Medicine Société anonyme | 14.5x | 48.2% | €19.4m |
DBV DBV Technologies | 4.4x | 59.6% | €52.1m |
ABNX ABIONYX Pharma | 9.4x | 40.7% | €45.8m |
AELIS Aelis Farma | 3.5x | 24.6% | €38.1m |
Price-To-Sales vs Peers: AELIS is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (7.4x).
Price to Sales Ratio vs Industry
How does AELIS's PS Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Sales vs Industry: AELIS is good value based on its Price-To-Sales Ratio (3.5x) compared to the French Biotechs industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is AELIS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.5x |
| Fair PS Ratio | 2.8x |
Price-To-Sales vs Fair Ratio: AELIS is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sanofi
€114.3b
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
SAN
€91.21
7D
-3.7%
1Y
6.9%
Theranexus Société Anonyme
€3.9m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€0.50
7D
-1.2%
1Y
-58.4%
Eurofins Scientific
€8.6b
Provides various analytical testing and laboratory services worldwide.
ERF
€45.50
7D
0.2%
1Y
-12.0%